Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Randomized, Phase 1b/2 Study of E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

NCT01332266 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01332266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01332266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Randomized, Phase 1b/2 Study of E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Eisai Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 19, 2011
Completion date
September 4, 2017
Enrollment
95 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant squamous cell carcinoma of the head and neck